

1. Record Nr.	UNINA9910595701003321
Autore	Curry Stephen H
Titolo	Drug Disposition and Pharmacokinetics : Principles and Applications for Medicine, Toxicology and Biotechnology
Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2022 ©2022
ISBN	9781119589198 9781119588436
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (480 pages)
Altri autori (Persone)	WhelptonRobin
Soggetti	Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Setting the Scene: Concepts, Nature of Drugs, and Quality of Results -- 1.1 Introduction -- 1.2 Concepts and terminology: disposition and pharmacokinetics -- 1.3 Pharmacokinetic parameters -- 1.3.1 Half-life -- 1.3.2 Clearance and apparent volume of distribution -- 1.3.3 Area under the plasma concentration-time curve -- 1.3.4 Apparent oral clearance -- 1.4 Time-concentration-effect relationships -- 1.5 Properties of drugs and xenobiotics -- 1.6 Quality of the data -- 1.6.1 Quantification of analyte concentrations -- 1.6.2 Timing of samples -- 1.6.3 Quality control and method validation -- 1.7 References -- Chapter 2 Drug Disposition and Fate -- 2.1 Introduction -- 2.2 Transport proteins -- 2.3 Absorption -- 2.3.1 Gastrointestinal tract -- 2.3.2 Drug transfer across the gastrointestinal tract -- 2.3.3 Other mucus membranes -- 2.3.4 Skeletal muscle -- 2.3.5 Skin -- 2.3.6 Absorption of macromolecules and nanoparticles -- 2.4 Distribution -- 2.4.1 Mechanisms of sequestration -- 2.4.2 Assessing the extent and location of distribution -- 2.4.3 Kinetics of distribution -- 2.5 Metabolism -- 2.5.1 Phase 1 metabolism -- 2.5.2 Phase 2 conjugations -- 2.5.3 Metabolism by microbiota -- 2.6 Excretion -- 2.6.1 Urine -- 2.6.2 Biliary excretion -- 2.6.3 Expired air -- 2.6.4 Saliva -- 2.6.5 Stomach and intestine -- 2.6.6 Breast milk -- 2.6.7 Other routes of excretion -- 2.6.8 Cycling processes -- 2.7

References -- Chapter 3 Pharmacokinetic Modelling -- 3.1 Introduction -- 3.2 Fundamental concepts -- 3.2.1 Apparent volume of distribution -- 3.2.2 Clearance -- 3.3 Elimination -- 3.3.1 First-order elimination -- 3.3.2 Non-linear elimination -- 3.4 Intravenous infusions -- 3.4.1 Single-compartment model with first-order elimination -- 3.4.2 Two-compartment model with first-order elimination. 3.5 First-order input and elimination -- 3.5.1 Absorption -- 3.5.2 Multiple dosing -- 3.6 Areas under the plasma concentration-time curve: trapezoidal method -- 3.7 Statistical moment theory -- 3.7.1 Estimating AUMC -- 3.8 Bioavailability and bioequivalence -- 3.8.1 Non-linear kinetics -- 3.8.2 Effect of systemic availability on plasma concentration-time curves -- 3.8.3 Factors affecting bioavailability -- 3.8.4 Bioequivalence -- 3.9 Physiological modelling -- 3.9.1 Practical considerations -- 3.10 Population kinetics -- 3.11 References -- Chapter 4 Pharmacokinetics of Metabolism and Excretion -- 4.1 Introduction -- 4.2 Metabolite kinetics -- 4.2.1 Basic concepts -- 4.2.2 Fraction of metabolite formed -- 4.2.3 More complex situations -- 4.2.4 Effect of pre-systemic metabolism -- 4.2.5 Interconversion of drug and metabolite -- 4.2.6 Active metabolites and prodrugs -- 4.2.7 Kinetics of formed and preformed metabolites -- 4.3 Kinetics of urinary excretion -- 4.3.1 Renal clearance -- 4.3.2 Effect of urine flow rate -- 4.3.3 Estimating renal blood flow and glomerular filtration rate -- 4.3.4 Specific drug examples -- 4.4 Excretion in faeces -- 4.5 References -- Chapter 5 Quantitative Pharmacological Relationships -- 5.1 Introduction -- 5.2 Concentration-effect relationships and dose-response curves -- 5.3 Concentration-effect relationships in vivo -- 5.4 Time-Dependent Models -- 5.4.1 Direct link and indirect link models -- 5.4.2 Temporal displacement -- 5.4.3 Inhomogeneity of plasma -- 5.4.4 Effects of unequal distribution in plasma -- 5.4.5 Pharmacokinetic distributional models -- 5.5 PK-PD modelling -- 5.5.1 PK-PD modelling under steady-state conditions -- 5.5.2 Use of effect-compartment models -- 5.5.3 Indirect-response models -- 5.5.4 Disease progression models -- 5.5.5 Time-related changes in pharmacodynamic parameters -- 5.5.6 Schedule dependence. 5.5.7 Basic PK-PD versus system PK-PD -- 5.6 References -- Chapter 6 Predictive Pharmacokinetics -- 6.1 Introduction -- 6.2 Physiochemical properties -- 6.2.1 Druggability -- 6.2.2 Drug-likeness -- 6.2.3 Dissolution studies -- 6.3 Metabolic stability -- 6.3.1 Microsomal intrinsic clearance -- 6.3.2 Hepatocytes -- 6.3.3 Recombinant human cytochromes -- 6.4 Plasma protein and tissue binding and blood/plasma ratios -- 6.4.1 Plasma protein binding -- 6.4.2 Erythrocyte concentrations -- 6.5 Hepatic clearance -- 6.5.1 Hepatic intrinsic clearance -- 6.5.2 Effect of plasma protein binding on elimination kinetics -- 6.6 Experimental methods of assessing transfer across biological membranes -- 6.6.1 Cell culture -- 6.6.2 Parallel artificial membrane permeability assay -- 6.6.3 Ussing chambers -- 6.6.4 Intestinal sacs -- 6.6.5 In vivo/in situ studies -- 6.7 Allometric scaling -- 6.7.1 Refinements to allometric scaling -- 6.7.2 Practical aspects of allometry -- 6.7.3 Method of Wajima -- 6.8 In silico predictions and PBPK modelling -- 6.9 Microdosing studies -- 6.10 Translational science -- 6.11 References -- Chapter 7 Disposition of Peptides and Other Biological Molecules -- 7.1 Introduction -- 7.2 Chemical aspects -- 7.2.1 PEGylation -- 7.3 Assay methods -- 7.4 Pharmacokinetics -- 7.4.1 Administration and dosage -- 7.4.2 Bioequivalence and biosimilarity -- 7.4.3 Distribution -- 7.4.4 Metabolism -- 7.4.5 Excretion -- 7.5 Plasma kinetics and pharmacodynamics -- 7.6 Examples of particular interest -- 7.6.1 Botulinum toxins -- 7.6.2 Cholecystokinins -- 7.6.3 Ciclosporin --

7.6.4 Cocaine hydrolases -- 7.6.5 Erythropoietin -- 7.6.6 Heparin --
7.6.7 Mipomersen -- 7.6.8 Somatotropin -- 7.6.9 Vasopressin
and desmopressin -- 7.7 References -- Chapter 8 Monoclonal
Antibodies -- 8.1 Introduction -- 8.2 Nomenclature -- 8.3 Circulation
of monoclonal antibodies.
8.3.1 Convection -- 8.3.2 Neonatal Fc receptor -- 8.3.3 Binding
to soluble target antigens -- 8.4 Pharmaceutical and DMPK aspects --
8.4.1 Routes of administration -- 8.4.2 Distribution and apparent
volume of distribution -- 8.4.3 Metabolism and excretion -- 8.4.4
Pharmacokinetics -- 8.4.5 Individual and population pharmacokinetics
-- 8.5 Development of orally administered monoclonal antibodies --
8.6 Optimizing pharmacokinetic and pharmacodynamic properties --
8.7 Two highlighted early and durable examples -- 8.7.1 Trastuzumab
-- 8.7.2 Adalimumab -- 8.8 PBPK modelling -- 8.9 Antibody-drug
conjugates -- 8.9.1 Payloads -- 8.9.2 Linkers -- 8.9.3 Bystander killing
-- 8.9.4 Disposition and pharmacokinetics -- 8.10 References --
Chapter 9 Drug Metabolism and Pharmacokinetics in Veterinary
Sciences -- 9.1 Introduction -- 9.2 Areas of practice -- 9.2.1
Companion animal medicine -- 9.2.2 Treatment of animals
of commerce -- 9.2.3 Zoos and wildlife preserves -- 9.2.4 Laboratory
animal medicine -- 9.3 Scientific approach including allometric scaling
-- 9.4 Information organized by pharmacokinetic processes -- 9.4.1
Administration -- 9.4.2 Absorption -- 9.4.3 Tissue distribution --
9.4.4 Plasma protein binding and transporters -- 9.4.5 Metabolism --
9.4.6 Excretion -- 9.5 Information organized by species and drugs --
9.5.1 Mammals -- 9.5.2 Fish -- 9.6 Some drugs unique to veterinary
science -- 9.7 Accidental exposure: toxicology - drugs used by
humans that are dangerous to animals -- 9.7.1 Paracetamol in cats --
9.7.2 Xanthines: chocolate in dogs -- 9.8 Residue analysis -- 9.9
References -- Chapter 10 Factors Affecting Plasma Concentrations:
Consideration of Special Populations -- 10.1 Introduction -- 10.2
Pharmaceutical factors -- 10.3 Weight and obesity -- 10.3.1 Effects
of obesity on pharmacokinetics -- 10.3.2 Dose adjustment in obesity.
10.3.3 Oral contraceptives -- 10.3.4 Gastric bypass surgery -- 10.3.5
Psychiatric patients -- 10.4 Food, diet, and nutrition -- 10.4.1 Diet
and nutrition -- 10.5 Time of day -- 10.5.1 Circadian rhythms --
10.5.2 Absorption -- 10.5.3 The liver -- 10.5.4 The kidneys -- 10.5.5
Intravenous and other injected doses -- 10.5.6 Pharmacodynamics --
10.6 Posture and exercise -- 10.6.1 Exercise -- 10.7 Smoking -- 10.8
References -- Chapter 11 Pharmacogenetics, Pharmacogenomics, and
Precision Medicine -- 11.1 Introduction -- 11.1.1 Terminology -- 11.2
Methods for the study of pharmacogenetics -- 11.2.1 Studies in twins
-- 11.2.2 Phenotyping and genotyping -- 11.3 N-Acetyltransferase --
11.3.1 Isoniazid -- 11.3.2 Sulfonamides -- 11.3.3 Other drugs --
11.3.4 Genotyping N-acetyltransferase -- 11.4 Plasma cholinesterase
-- 11.4.1 Suxamethonium -- 11.5 Carboxylesterases -- 11.6
Cytochrome P450 polymorphisms -- 11.6.1 Cytochrome 2D6 -- 11.6.2
Cytochrome 2C9 -- 11.6.3 Cytochrome 2C19 -- 11.6.4 Cytochromes
3A4/5 -- 11.6.5 Other cytochrome P450 polymorphisms -- 11.7
Glucose-6-phosphate dehydrogenase -- 11.7.1 Glucose-6-phosphate
dehydrogenase deficiency -- 11.7.2 Triggering -- 11.7.3 Effects
on pharmacokinetics -- 11.8 Alcohol dehydrogenase and acetaldehyde
dehydrogenase -- 11.9 Thiopurine methyltransferase -- 11.10 Phase 2
enzymes -- 11.10.1 UDP-glucuronosyltransferases -- 11.10.2
Sulfotransferases -- 11.10.3 Glutathione transferases -- 11.11
Transporters -- 11.12 Pharmacodynamic differences -- 11.13 Ethnicity
-- 11.14 Personalized medicine -- 11.15 References -- Chapter 12
Effects of Sex and Pregnancy on Drug Disposition and Pharmacokinetics

-- 12.1 Introduction -- 12.1.1 Studies in animals -- 12.2 Effect of sex on human drug disposition and pharmacokinetics -- 12.2.1 Absorption and bioavailability -- 12.2.2 Distribution -- 12.2.3 Metabolism -- 12.2.4 Excretion. 12.2.5 Effects.
